The position of bopindolol
a new β-blocker

Edited by
P. A. van Zwieten

Royal Society of Medicine Services
London  New York
1987
## Contents

Contributors ........................................... v

Preface .................................................. ix

Different properties of $\beta$-adrenoceptor blockers; characteristics of bopindolol
P. A. van Zwieten ....................................... 1

Reduction in lymphocyte $\beta_2$-adrenoceptor density, caused by $\beta$-adrenoceptor antagonists with ISA: a possible explanation for the absence of "rebound-effects"
O. Galal, X. L. Wang and O.-E. Brodde ................. 13

$\beta$-Blockers in hypertension
A. J. Man in 't Veld ..................................... 21

Acute and long-term haemodynamic effects of bopindolol
A. H. van den Meiracker, A. J. Man in 't Veld and M. A. D. H. Schalekamp 35

Influence of bopindolol and atenolol on 24-hour cardiac frequency
P. Fitscha, W. Meisner and B. Tiso ...................... 43

Pharmacokinetic and pharmacodynamic arguments for the explanation of the long action of bopindolol
J. Grevel .................................................. 49

Antihypertensive and metabolic effects of bopindolol at rest and during exercise— is once weekly dosage possible?
O. K. Andersson, T. Hedner and G. Nyberg ............... 55

Bopindolol-induced changes in plasma lipid fractions in hypertensive patients
P. van Brummelen and F. R. Bühler ...................... 63

Age-independence of the antihypertensive efficacy of $\beta$-blocker treatment
P. Weidmann, J. C. Bousquet and the Swiss Practitioners Bopindolol Study Group 67
Bopindolol vs metoprolol in hypertension: comparison of clinical efficacy and tolerance in a double-blind, parallel study
R. F. Westerman, C. Christensen, A. Westheim and A. J. M. Donker 75

Bopindolol vs metoprolol in patients with hypertension and a left ventricular ejection fraction less than 55%
S. H. Braat, A. P. M. Gorsels and E. Hardy 83

Efficacy of bopindolol, a new β-blocking agent in angina pectoris compared to metoprolol
A. Vermeulen 87

Conclusions: the profile of bopindolol
P. A. van Zwieten 91